Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/52813
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDoğan, Tolga-
dc.contributor.authorYaren, Arzu-
dc.contributor.authorDemiray, Atike Gökçen-
dc.contributor.authorYapar Taşköylü, Burcu-
dc.contributor.authorÇakar Demirel, Burçin-
dc.contributor.authorÖzdemir, Melek-
dc.contributor.authorGüçlü Kantar, Taliha-
dc.contributor.authorDeğirmencioğlu, Serkan-
dc.contributor.authorGököz Doğu, Gamze-
dc.date.accessioned2023-10-27T07:06:04Z-
dc.date.available2023-10-27T07:06:04Z-
dc.date.issued2023-
dc.identifier.issn1309-9833-
dc.identifier.urihttps://doi.org/10.31362/patd.1265291-
dc.identifier.urihttps://hdl.handle.net/11499/52813-
dc.description.abstractPurpose: We evaluated the effect of pre-treatment inflammation response markers on overall survival (OS) and progression-free survival (PFS) in patients with locally advanced unresectable and metastatic gastric cancer. Material and method: Patients with locally advanced unresectable and metastatic gastric cancer between January 2016 and December 2021 were included. Among these patients, 114 patients with ECOG (Eastern Cooperative Oncology Group) Performance status 0-2, who received at least one line of chemotherapy, had no comorbidities and brain metastases were included in the study. Pre-treatment platelet, lymphocyte, leukocyte, neutrophil, monocyte, albumin, C-reactive protein (CRP), lactatedehydrogenase (LDH) levels, histology types, age, surgical history, treatment history and ECOG Performance status were retrospectively analysed from their records. Threshold values were determined by ROC analysis. Kaplan-Meier survival analyses were used for survival analyses. Hazard ratio (HR) and confidence intervals (CI) of the factors affecting overall survival (OS) and progression-free survival (PFS) were calculated using Coxproportional-hazards model. Results: The median age of the patients was 63.5±11.9 (28-80). Among the patients, 69 (60.5%) were in metastatic stage. 106 (93.0%) patients had poorly differentiated carcinoma histology. Progression developed in 88.6% (101) of patients and 98 patients (86%) were deceased. In the whole group, mPFS was 9.4±0.9 (95%CI 7.7-11.0) months and mOS was 14.1±1.6 (95%CI 10.8-17.2) months. When the Coxproportional-hazards model was used, the factors affecting OS were advanced age, metastatic stage, neutrophil lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR), derived neutrophil lymphocyte ratio (dNLR) and lactate dehydrogenase (LDH), while the factors affecting PFS were advanced age, metastatic stage, NLR, dNLR and LDH. Conclusion: While NLR, PLR, dNLR, dNLR and LDH affect OS, LDH affects PFS. Systemic inflammatory markers of locally advanced unresectable and metastatic gastric cancers before chemotherapy can be used to predict prognosis. © 2023, Pamukkale University. All rights reserved.en_US
dc.language.isoenen_US
dc.publisherPamukkale Universityen_US
dc.relation.ispartofPamukkale Medical Journalen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectGastric canceren_US
dc.subjectneutrophil-lymphocyte ratioen_US
dc.subjectplatelet-lymphocyte ratioen_US
dc.subjectprognosisen_US
dc.titleThe effect of pre-treatment inflammatory response markers on survival in locally advanced unresectable and metastatic gastric cancer: a retrospective cross-sectional studyen_US
dc.title.alternativeLokal ileri rezeke edilemeyen ve metastatik mide kanserinde tedavi öncesi inflamasyon yanıtı belirteçlerinin sağkalım üzerine etkisien_US
dc.typeArticleen_US
dc.identifier.volume16en_US
dc.identifier.issue3en_US
dc.identifier.startpage434en_US
dc.identifier.endpage445en_US
dc.departmentPamukkale Universityen_US
dc.identifier.doi10.31362/patd.1265291-
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.authorscopusid33367894800-
dc.authorscopusid12759416700-
dc.authorscopusid57200169071-
dc.authorscopusid36961379700-
dc.authorscopusid35329601700-
dc.authorscopusid57197179294-
dc.authorscopusid58535992100-
dc.identifier.scopus2-s2.0-85167923637en_US
dc.identifier.trdizinid1193068en_US
dc.institutionauthor-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeArticle-
item.cerifentitytypePublications-
item.fulltextWith Fulltext-
item.grantfulltextopen-
item.languageiso639-1en-
crisitem.author.dept14.02. Internal Medicine-
crisitem.author.dept14.02. Internal Medicine-
crisitem.author.dept14.02. Internal Medicine-
crisitem.author.dept14.02. Internal Medicine-
crisitem.author.dept14.02. Internal Medicine-
crisitem.author.dept14.02. Internal Medicine-
crisitem.author.dept14.02. Internal Medicine-
crisitem.author.dept14.02. Internal Medicine-
crisitem.author.dept14.02. Internal Medicine-
Appears in Collections:Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
TR Dizin İndeksli Yayınlar Koleksiyonu / TR Dizin Indexed Publications Collection
Show simple item record



CORE Recommender

Page view(s)

52
checked on Aug 24, 2024

Download(s)

20
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.